Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca PLC stock logo
AZN
AstraZeneca
$70.10
+0.0%
$70.55
$61.24
$87.68
$217.46B0.385.20 million shs1.37 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$70.10
+0.0%
$70.55
$61.24
$87.68
$217.46B0.385.20 million shs1.37 million shs
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
(MDVN) stock logo
MDVN
(MDVN)
$81.44
$0.00
$26.41
$81.48
N/AN/A3.55 million shsN/A
Pfizer Inc. stock logo
PFE
Pfizer
$24.29
+0.2%
$23.42
$20.92
$31.54
$138.01B0.5741.17 million shs10.09 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.29
+0.2%
$23.42
$20.92
$31.54
$138.01B0.5741.17 million shs10.09 million shs
Tesaro, Inc. stock logo
TSRO
Tesaro
$74.96
$0.00
$23.41
$75.16
$4.13B0.381.97 million shs1.19 million shs
Tesaro, Inc. stock logo
TSRO
Tesaro
$74.96
$0.00
$23.41
$75.16
$4.13B0.381.97 million shs1.19 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.56%-0.98%-1.25%-5.04%-11.39%
AstraZeneca PLC stock logo
AZN
AstraZeneca
+0.56%-0.98%-1.25%-5.04%-11.39%
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
(MDVN) stock logo
MDVN
(MDVN)
0.00%0.00%0.00%0.00%0.00%
Pfizer Inc. stock logo
PFE
Pfizer
+0.06%+1.80%+2.94%-3.56%-11.36%
Pfizer Inc. stock logo
PFE
Pfizer
+0.06%+1.80%+2.94%-3.56%-11.36%
Tesaro, Inc. stock logo
TSRO
Tesaro
0.00%0.00%0.00%0.00%0.00%
Tesaro, Inc. stock logo
TSRO
Tesaro
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.2556 of 5 stars
2.43.01.70.02.90.01.3
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.2556 of 5 stars
2.43.01.70.02.90.01.3
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
(MDVN) stock logo
MDVN
(MDVN)
N/AN/AN/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
4.8604 of 5 stars
2.33.04.24.32.91.73.1
Pfizer Inc. stock logo
PFE
Pfizer
4.8604 of 5 stars
2.33.04.24.32.91.73.1
Tesaro, Inc. stock logo
TSRO
Tesaro
N/AN/AN/AN/AN/AN/AN/AN/A
Tesaro, Inc. stock logo
TSRO
Tesaro
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.83
Moderate Buy$85.0021.26% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.83
Moderate Buy$85.0021.26% Upside
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
(MDVN) stock logo
MDVN
(MDVN)
0.00
N/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1720.10% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1720.10% Upside
Tesaro, Inc. stock logo
TSRO
Tesaro
0.00
N/AN/AN/A
Tesaro, Inc. stock logo
TSRO
Tesaro
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MDVN, AZN, CLVS, PFE, TSRO, PFE, TSRO, AZN, and CLVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.02$6.33 per share11.07$13.18 per share5.32
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.07B4.02$6.33 per share11.07$13.18 per share5.32
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
(MDVN) stock logo
MDVN
(MDVN)
N/AN/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.17$4.37 per share5.56$15.62 per share1.55
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.17$4.37 per share5.56$15.62 per share1.55
Tesaro, Inc. stock logo
TSRO
Tesaro
$223.33M18.48N/AN/A$4.58 per share16.37
Tesaro, Inc. stock logo
TSRO
Tesaro
$223.33M18.48N/AN/A$4.58 per share16.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4928.1614.021.2814.14%33.14%12.83%7/24/2025 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4928.1614.021.2814.14%33.14%12.83%7/24/2025 (Estimated)
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
(MDVN) stock logo
MDVN
(MDVN)
N/AN/A0.00N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.598.010.8812.62%20.33%8.53%8/5/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.598.010.8812.62%20.33%8.53%8/5/2025 (Estimated)
Tesaro, Inc. stock logo
TSRO
Tesaro
-$496.12M-$9.17N/AN/AN/A-295.67%-1,209.72%-83.34%N/A
Tesaro, Inc. stock logo
TSRO
Tesaro
-$496.12M-$9.17N/AN/AN/A-295.67%-1,209.72%-83.34%N/A

Latest MDVN, AZN, CLVS, PFE, TSRO, PFE, TSRO, AZN, and CLVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.11N/AN/AN/AN/AN/A
7/24/2025Q2 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.11N/AN/AN/AN/AN/A
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.94%N/A82.73%N/A
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.94%N/A82.73%N/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
(MDVN) stock logo
MDVN
(MDVN)
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.08%N/A124.64%16 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.08%N/A124.64%16 Years
Tesaro, Inc. stock logo
TSRO
Tesaro
N/AN/AN/AN/AN/A
Tesaro, Inc. stock logo
TSRO
Tesaro
N/AN/AN/AN/AN/A

Latest MDVN, AZN, CLVS, PFE, TSRO, PFE, TSRO, AZN, and CLVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.90
0.70
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
(MDVN) stock logo
MDVN
(MDVN)
N/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A
3.40
2.83
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A
3.40
2.83

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
(MDVN) stock logo
MDVN
(MDVN)
87.55%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A

Insider Ownership

CompanyInsider Ownership
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
(MDVN) stock logo
MDVN
(MDVN)
3.54%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Tesaro, Inc. stock logo
TSRO
Tesaro
33.70%
Tesaro, Inc. stock logo
TSRO
Tesaro
33.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
94,3003.10 billionN/AOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
(MDVN) stock logo
MDVN
(MDVN)
N/AN/AN/ANot Optionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A55.05 millionN/AOptionable
Tesaro, Inc. stock logo
TSRO
Tesaro
N/A55.05 millionN/AOptionable

Recent News About These Companies

GSK enters PARP space with TESARO acquisition
Tesaro and Roche to combine drugs in bladder cancer trials
Hedge Fund - Ivory Capital (Investment Mgmt)
Tesaro stock rockets as rumours of Roche takeover abound
Biopharma Cred. Regulatory News
Gilbert H Kliman's Net Worth
Keval Desai's Net Worth

New MarketBeat Followers Over Time

Media Sentiment Over Time

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$70.10 +0.03 (+0.04%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$70.10 +0.03 (+0.04%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

(MDVN) stock logo

(MDVN) NASDAQ:MDVN

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Pfizer stock logo

Pfizer NYSE:PFE

$24.28 +0.05 (+0.19%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer stock logo

Pfizer NYSE:PFE

$24.28 +0.05 (+0.19%)
As of 12:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Tesaro stock logo

Tesaro NASDAQ:TSRO

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Tesaro stock logo

Tesaro NASDAQ:TSRO

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd., as well as Genentech. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.